<DOC>
	<DOCNO>NCT00005861</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal doxorubicin treat woman recurrent , stage III , stage IV endometrial cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Treating Patients With Advanced Recurrent Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity safety doxorubicin HCl liposome patient advance recurrent endometrial cancer . - Determine response rate , response duration , overall survival patient treat regimen . OUTLINE : Patients receive doxorubicin HCl liposome IV 1 hour . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 19-51 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III , IV , recurrent endometrial carcinoma curative radiotherapy surgery option Bidimensionally measurable disease Irradiated field site allow evidence progression since radiotherapy PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : LVEF normal cardiac echocardiogram MUGA Other : No concurrent active infection No prior concurrent malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy radiosensitizer allow No prior chemotherapy advance metastatic disease No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Recovered prior radiotherapy Surgery : See Disease Characteristics Recovered prior surgery Other : No prior therapy would preclude study No concurrent antineoplastic agent No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>